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Fungal infections, especially with the advent of antimicrobial resistance, represent a major 2 
burden to our society. As a result, there has been an increasing interest in the development 3 
of new probes that accelerate the study of fungi-related biological processes and facilitate 4 
novel clinical diagnostic and treatment strategies. Fluorescence-based reporters can provide 5 
dynamic information at the molecular level with high spatial resolution. However, conventional 6 
fluorescent probes for microbes often suffer from low specificity. In the last decade, numerous 7 
studies have been reported on the chemical design and application of fluorescent peptides for 8 
both in vitro and in vivo imaging of fungal cells. In this article, we review different strategies 9 
used in the preparation of fluorescent peptides for pathogenic fungi as well as some of their 10 
applications in medical imaging and in mode-of-action mechanistic studies. 11 




Fluorescence imaging has revolutionised our ability to study biological processes in cells and 2 
intact organisms with high spatial and temporal resolution [1-3]. In the last decades, multiple 3 
chemical approaches have been reported for the development of fluorescent probes that 4 
enable direct visualisation of biomolecules and cells. These encompass broad diversity-5 
oriented fluorescent libraries to identify novel biomarkers of cell states [4] as well as reactive 6 
fluorophores for targeted conjugation to small molecules and drugs [5-7]. Major advantages 7 
of fluorescent probes include: 1) high sensitivity with typically low limits of detection [8-10], 2) 8 
compatibility for multiplexed assays [11, 12], and 3) high versatility in multiple assay formats, 9 
from mechanistic studies [13, 14] to high-throughput screenings [15] and in vivo imaging [16]. 10 
 11 
Fungi are eukaryotic microorganisms with relative similarities to mammalian cells. Although 12 
most fungi are not pathogenic, several species can cause severe fungal infections in humans 13 
and plants. Globally, there are more than 1.5 billion people suffering from fungal infections, 14 
ranging from mild chronic superficial infections to life-threatening invasive infections caused 15 
by four main pathogenic fungi: Candida, Aspergillus, Cryptococcus and Pneumocystis. 16 
Furthermore, fungi are also a major cause of disease in crops, causing major environmental, 17 
social and economic burden. Currently there are only a few antifungal drugs used for treating 18 
such infections, and the resistance against them has been increasing at an alarming rate over 19 
the last years. The need for new strategies to combat antifungal resistance both in medicine 20 
and agriculture have prompted numerous studies to understand the mechanism of antifungal 21 
drugs as well as to develop new diagnostic tools with enhanced resolution and speed. To this 22 
end, fluorescence imaging has largely facilitated the development of novel diagnostics and 23 
treatments with improved selectivity for fungi over host cells and other pathogens [17-21]. 24 
 25 
Whereas fluorescent probes can be rationally designed to target specific targets or even cell 26 
types [22, 23], they are often conjugated to other chemical structures that confer them with 27 
molecular recognition properties for enhanced target specificity. These can include small 28 
molecules [24], antibodies [25] as well as peptides, among others. Peptides are excellent 29 
scaffolds for the preparation of fluorescent molecular probes. In addition to low cost and well-30 
established protocols for their parallel synthesis [26, 27], peptide conjugates can achieve high 31 
target specificity, including defined receptors and subtypes [28-31] as well as subcellular 32 
structures [32]. In this article, we will review some of the advances during the last decade in 33 
the preparation and evaluation of peptide-based imaging probes for the detection and 34 
characterisation of fungal cells, from in vitro cellular assays to in vivo imaging in animals and 35 




1. Fluorescent peptides for optical imaging of pathogenic fungi 1 
Fungal cells display differential patterns of phospholipid and sterol composition in membranes 2 
when compared to mammalian cells (e.g., ergosterol instead of cholesterol) [33], yet there are 3 
still limited fluorescent contrast agents with high specificity for fungal cells [34]. Ideally, 4 
fluorescent probes for imaging fungal cells must exhibit: 1) strong binding to fungi-specific 5 
components, 2) specific uptake and retention, and 3) high chemical and photo-stability. 6 
Peptides have been increasingly recognised as promising scaffolds to generate agents for 7 
molecular imaging, partially due to their ability to form highly specific interactions with their 8 
respective targets [35-37]. This section summarises recent progress on the preparation and 9 
application of fluorescent peptides for optical imaging of fungal cells in vitro and in vivo. 10 
 11 
1.1. Fluorescent peptides for live-cell imaging 12 
Most peptides do not contain functional groups that allow direct visualisation by live-cell 13 
fluorescence imaging. Therefore, reporters such as fluorophores are introduced to enhance 14 
the contrast between targeted cells and their background [38]. Fluorescent peptides are 15 
versatile agents for multiple applications, from live-cell imaging with subcellular resolution to 16 
in vivo detection of fungal infections in preclinical models. Fluorescent peptides and 17 
peptidomimetics for fungal cells have provided insights on the mode-of-action of antimicrobial 18 
peptides and have also allowed researchers to visualise biological processes associated to 19 
fungal growth in real time.  20 
Fluorescent peptides for imaging of fungal cells benefit from the fact that fungi are larger than 21 
most microorganisms (e.g., bacteria). To date, several antifungal peptides have been labelled 22 
with fluorophores to perform live-cell imaging studies in various fungal strains. Rhodamine-23 
labelled MtDef4 and Dylight550-labelled MtDef5 (both plant defensins) were employed for 24 
imaging cell entry and subcellular localisation in two ascomycete fungi: the model fungus 25 
Neurospora crassa and the pathogenic fungus Fusarium graminearum. These studies helped 26 
to gain insights into the mechanism by which defensins exert their antifungal activity [39-41]. 27 
Subsequently, Muñoz et al. reported that both plant defensins MtDef1 and MtDef4 and their 28 
cognate peptides exhibited different inhibitory effects in the germination and fusions of N. 29 
crassa. In order to examine the correlation between their antifungal activity and intracellular 30 
localisation, rhodamine-labelled fluorescent analogues of the cognate peptides MtDef4, 31 
GMA4-C and GMA4-L were prepared and tested to reveal that their different subcellular 32 
distributions were associated with variable levels of inhibitory activity [42].  33 
 34 
Puig et al. described a concentration-dependent membrane permeabilisation mechanism for 35 
the antifungal peptide BP15 in the pathogenic fungus Stemphylium vesicarium [43]. 36 
Fluorescein-labelled BP15 was shown to interact with the cell periphery and later internalise 37 
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within the hyphae. The authors also demonstrated that BP15 could not permeabilise or enter 1 
conidial cells (i.e., reproductive spores), suggesting the potential use of BP15 for controlling 2 
fungal infection in plants and crops [44]. Maurya et al. described an interesting application of 3 
fluorescent peptides as mode-of-action exploratory probes to study resistance mechanisms in 4 
the human pathogenic fungus Candida albicans [45]. The authors prepared fluorescent 5 
analogues of the transmembrane peptide mimics (TMPMs) targeting the efflux pump Cdr1, 6 
which is one of the most predominant targets in azole-resistant C. albicans from clinical 7 
isolates. Fluorescein-labelled TMPMs were used to study their interaction with the 8 
transmembrane helices of Cdr1 protein and proved to block the efflux of fluorescent agents 9 
from the azole-resistant C. albicans. This study has opened new avenues in the development 10 
of TMPMs as Cdr1 inhibitors to overcome multidrug resistance in C. albicans infections. The 11 
same research group has also reported two other antifungal peptides (i.e., VS2 and VS3) 12 
which exhibit cytotoxic activity against various pathogenic species. Fluorescein-labelled VS2 13 
and VS3 were used to analyse the kinetics of permeabilisation and also the resulting 14 
intracellular accumulation of the peptides. Their results suggested that peptides could make 15 
the cell membrane permeable to other molecules that are unable to internalise on their own. 16 
This allowed both VS2 and VS3 to work synergistically with other antifungals such as 17 
fluconazole to exhibit an improved antifungal activity [46]. 18 
 19 
PAF26 is one of the most studied short antifungal peptides. It was identified from a 20 
combinatorial positional scanning antimicrobial peptide library and it shows preferential activity 21 
toward filamentous fungi over other tested microorganisms [47] with minimal cytotoxicity in 22 
human red blood cells [48] and keratinocytes [49]. Muñoz et al. prepared fluorescent 23 
analogues of PAF26 by incorporation of carboxytetraaminomethylrhodamine (TAMRA) and 24 
fluorescein isothiocyanate (FITC) and used them for live-cell imaging in combination with 25 
additional dyes (i.e., FM-4-64 as a membrane and endocytosis-staining dye, cDFFDA as a 26 
vacuolar dye, and propidium iodide as a dead cell marker). The authors observed that 27 
fluorescently-labelled PAF26 derivatives exhibited concentration-dependent penetration and 28 
cytotoxicity in N. crassa [50]. At high concentrations, PAF26 was primarily translocated across 29 
the plasma membrane by passive diffusion and exerted its fungicidal effect via an energy-30 
independent progress. On the other hand, at low concentrations PAF26 exhibited a different 31 
mechanism. Upon interaction with the fungal cell envelope, the peptide showed a progressive 32 
uptake through endocytosis with accumulation in vacuoles and subsequent transport to the 33 
cytoplasm coinciding with cell death [50]. Similarly, the antifungal peptide histatin-5 was also 34 
reported to display a concentration-dependent mechanism on its fungicidal action in C. 35 
albicans. At low concentrations, histatin-5 was internalised via receptor-mediated endocytosis 36 
into cell vacuoles, whereas the direct translocation through the plasma membrane was 37 
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reported at higher concentrations [51, 52]. Although PAF26 and histatin-5 are both positively-1 
charged peptides, their chemical structures are remarkably different. PAF26 is a 6-mer 2 
whereas histatin-5 is a 24-mer, thus it is noteworthy that they exhibit similar concentration-3 
dependent mechanisms of internalisation and antifungal activity. In another study, Ordonez et 4 
al. performed real-time tracking of the internalisation of fluorescent analogues of the human 5 
cathelicidin peptide LL-37 and the chicken cathelicidin 2 (CATH-2) in C. albicans. The authors 6 
showed that both LL-37 and CATH-2 exhibited rapid strong membrane staining, however their 7 
internalisation was energy-independent, suggesting direct membrane permeabilisation as the 8 
main mechanism of action [53]. Unlike histatin-5 and PAF26, both LL-37 and CATH-2 showed 9 
lack of fungal specificity and rather general antimicrobial properties, with almost identical 10 
mode-of-action in different non-fungal microorganisms [54-56]. Furthermore, several other 11 
short antimicrobial cationic peptides that exhibit endocytosis-independent internalisation have 12 
been reported to be non-specific for fungal cells. These results indicate that the initial 13 
interactions between PAF26 and histatin-5 with the fungal cell envelope are critical for their 14 
fungal selectivity over other microorganisms and suggest that biomolecules in the fungal cell 15 
envelope might be potential targets. The fact that both PAF26 and histatin-5 need to be 16 
translocated to the cytosol to exert their fungicidal action also suggests that they may also 17 
have additional intracellular targets [52, 57]. 18 
 19 
Apart from the membrane-targeting mechanism discussed above, Iida et al. reported a 20 
vacuolar-targeting mechanism for polymyxin B in Saccharomyces cerevisiae. Polymyxin B is 21 
known as a cationic cyclic peptide that inhibits Gram-negative bacteria by targeting 22 
lipopolysaccharide and disrupting the outer bacterial membrane [58, 59]. It is worth noting that, 23 
by conjugating an environmentally-sensitive fluorophore (i.e., dansyl), the authors could 24 
observe the accumulation of polymyxin B in the vacuoles of fungal cells lacking 25 
lipopolysaccharide, suggesting a different mode-of-action in fungal cells. [60] 26 
 27 
The studies mentioned above demonstrate the utility of fluorescent peptides for in situ analysis 28 
of antifungal activity, however the impact of the fluorophores on the properties of the peptides 29 
have not been extensively evaluated. Most studies employ commercially available 30 
fluorophores that are conjugated to the N- or C- terminal groups. This strategy may cause 31 
alterations in short peptide sequences and might compromise their biological activity. To 32 
address this issue, Zhao et al. recently conducted a systematic combinatorial study to analyse 33 
the influence of different fluorophores on the hexapeptide PAF26 by preparing 12 different 34 
fluorescent analogues and comparing their cellular uptake and distribution using confocal live-35 
cell imaging [61]. PAF26 was employed as a representative antimicrobial peptide with both 36 
cationic and hydrophobic regions. In addition to widely used fluorophores (e.g., TAMRA, 37 
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FITC), another 10 fluorophores covering the whole UV-visible spectrum (i.e., from blue to near-1 
infrared fluorescence) and with variable physicochemical properties were used for labelling 2 
PAF26. This selection included conventional fluorescent scaffolds (e.g., cyanine, BODIPY), 3 
environmentally-sensitive dyes (e.g., NBD, dansyl, Nile Blue), pH-sensitive dyes (e.g., 4 
naphthalimide) and esterase-activatable fluorophores (e.g., fluorescein diacetate). By careful 5 
evaluation of the library, the authors concluded that the incorporation of different fluorophores 6 
into the sequence of PAF26 significantly influenced its intracellular localisation. Positively-7 
charged fluorophores (e.g., styryl) favoured the interaction with anionic membranes, whereas 8 
negatively-charged fluorophores (e.g., FITC) preferentially accumulated in intracellular 9 
vacuoles. Near-infrared fluorophores (e.g., cyanine) provided bright cytosolic staining and 10 
good discrimination from background signals, both in vitro and using whole-body in vivo 11 
fluorescence imaging. Additionally, the pH-sensitive fluorophores naphthalimide facilitated the 12 
visualisation of vacuolar acidification in fungal cells. These results suggest that peptides 13 
including bespoke fluorophores may represent a good strategy to visualise specific 14 
intracellular processes in fungal cells with subcellular resolution. 15 
 16 
1.2. Fluorescent peptides for ex vivo tissue and in vivo imaging 17 
Over the past decades, medical imaging technologies have emerged as powerful tools for 18 
early-stage diagnosis and non-invasive monitoring of disease progression, including patient 19 
stratification and response to therapy [62, 63]. Peptide-based optical probes have been 20 
increasingly applied for different pathological conditions, including cancer and bacterial 21 
infections, largely due to their good target specificity, marginal cytotoxicity and low 22 
immunogenicity [64]. However, imaging fungal infection still remains largely unexplored in the 23 
medical arena, with only a few successful examples of peptide-based imaging probes. 24 
 25 
C. albicans is a common pathogenic fungus in humans that can cause skin, oral 26 
gastrointestinal and urogenital infections as well as fatal systemic infections in 27 
immunocompromised patients [65, 66]. For the infections to grow, C. albicans need to first 28 
aggregate and adhere to host cells. Of note, the biofilms formed by the fungal cells increase 29 
the resistance against conventional antimicrobial treatments [67, 68]. The C. albicans 30 
agglutinin-like sequence (Als) form functional amyloid patches on the surface of host cells and 31 
plays an important role in cell adhesion and biofilm formation during the development of the 32 
infection [69-71]. Garcia et al. reported the development of a fluorescent amyloid-forming 33 
peptide Als-5p able to bind C. albicans in both yeast and hyphal forms. The authors also 34 
demonstrated that the fluorescent peptide Als-5p could bind to fungi in gastrointestinal tissue 35 
samples from candidiasis patients [72]. Compared to traditional amyloid-binding dyes, such 36 
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as thioflavin T, the fluorescent Als-5p peptide probe showed good selectivity for amyloids of 1 
fungal origin.  2 
 3 
Invasive pulmonary aspergillosis (IPA) is a fatal infection caused by Aspergillus species in 4 
immunocompromised patients. Current diagnostic approaches rely on cultures from 5 
bronchoalveolar lavage fluid and peripheral blood, which are time-consuming and lead to 6 
mortality rates of IPA patients over 40% due to inefficient diagnostic tools [73]. Mendive-Tapia 7 
et al. described a novel peptide-based imaging probe with selective binding to A. fumigatus in 8 
ex vivo human lung tissue [32, 74] (Figure 1). Notably, the authors developed a peptide with 9 
a fluorogenic core for real-time imaging of fungal species in situ, without the need of additional 10 
washing steps. In other studies, Morisse et al. and Akram et al. conducted assays using 11 
fluorescent peptides in fiber-based confocal fluorescence endomicroscopy (FCFM) [75, 76]. 12 
Pioneered by Thiberville and co-workers, FCFM allows in vivo imaging of lung microstructures 13 
during bronchoscopy [77]. Morisse et al. employed a fluorescein-labelled cyclic peptide while 14 
Akram et al. employed an NBD-labelled peptide, both showing good selectivity for fungi over 15 
host cells. All these studies provide innovative strategies for the future development of 16 
improved IPA diagnostic tools. 17 




Figure 1. Fluorescence images of A. fumigatus in vitro and in ex vivo human tissue. a) 2 
High-resolution fluorescence confocal images of the fungal pathogen A. fumigatus after 3 
incubation with a cell membrane counterstain (red) and following addition of the fluorescent 4 
peptide 8 (2 µM, green). Peptide 8 initially interacts rapidly with the apical plasma membrane 5 
of A. fumigatus, and its staining then shifts toward the base of the germling cell within a few 6 
minutes. λexc: 496 nm, λem: 505–550 nm (green); λexc: 570 nm, λem: 585–650 nm (red). Scale 7 
bar: 5 µm. b) Multi-photon fluorescence microscopy of ex vivo human pulmonary tissue after 8 
incubation with RFP-expressing A. fumigatus and peptide 8. Fluorescence images of peptide 9 
8 (5 µM) (A), RFP-expressing A. fumigatus (B), second harmonic generation from collagen 10 
fibres (C) and merged (D) in ex vivo human lung tissue. Scale bar: 10 µm. Images reproduced 11 
with permission from references 32 (a) and 74 (b). 12 
 13 
Fungal keratitis (FK) is a major cause of ocular morbidity and blindness. It globally affects 14 
contact lens wearers and patients experiencing trauma in the eye. FK infections are 15 
predominantly caused by two fungal genera, Aspergillus and Fusarium. Around 50% of FK 16 
patients lose sight in the infected eye and over 13,000 eyes are lost completely per year in 17 
worldwide [78, 79]. Early diagnosis of FK is critical to ensure the best possible therapeutic 18 
outcome. However, current diagnosis relies on direct in vivo confocal microscopy (IVCM) and 19 
microbiological culture of corneal scrapings [80]. IVCM requires expensive equipment and is 20 
mostly limited to well-resourced hospitals. Microbiological cultures of corneal scrapings reveal 21 
infections in 40-85% of cases, but they take weeks and can miss deep infections. Therefore, 22 
the development of safe, rapid, and sensitive diagnostic probes is necessary to improve early-23 
stage FK diagnosis. Lee et al. recently reported the lipopeptide caspofungin coupled to near-24 
infrared fluorophore DDAO (CSF-DDAO) as a tomographic imaging probe for rapid FK 25 
diagnosis [81]. The authors demonstrated that CSF-DDAO efficiently labelled various 26 
Aspergillus species in vitro. They also used a liposome-encapsulated CSF-DDAO for the 27 
detection of various species including A. fumigatus, A. niger and A. flavus in a mouse model 28 
10 
 
of FK within 10 min of post topical application (Figure 2). This study constitutes an excellent 1 




Figure 2. Fluorescence imaging of fungal keratitis in mice. SKH1 mice infected 6 
intrastromally with A. fumigatus, A. flavus or A. niger were tomographically imaged 24 h post-7 
infection at the indicated time points (i.e., pre-exposure, 5, 30, 50, and 60 min post-exposure) 8 
with the CSF-DDAO probe using the 680 nm fluorescence emission filter. Fluorescence-based 9 
quantification for the probe (in picomoles) is shown for every image and depicted on the 10 
intensity map. Images reproduced with permission from reference 81. 11 
 12 
 13 
  14 
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2. Fluorescent peptide nucleic acids for in situ hybridisation 1 
Fluorescence in situ hybridisation based on peptide nucleic acids (PNA-FISH) is a commercial 2 
Food and Drug administration (FDA)-approved assay for the detection and identification of 3 
invasive microbial infections [82]. This method is based on fluorescently-labelled PNA probes 4 
that recognise and bind to complementary ribosomal RNA regions of microorganisms for direct 5 
identification at a single-cell level. Notably, because these agents show high susceptibility to 6 
small changes on target RNA sequences, they are also able to discriminate between closely-7 
related pathogens. Several PNA-FISH assays targeting either 18S, 26S or 28S rRNA regions 8 
of Candida species have been described [83, 84]. PNA probes are synthetic DNA mimics 9 
comprising a hydrophobic and uncharged polyamide-type backbone to which individual 10 
nucleobases are attached. Thus, the hydrophobic nature of the probe facilitates permeability 11 
-although methanol fixation is often used- and the lack of electrostatic repulsion leads to 12 
stronger binding to the target sequence and faster hybridisation kinetics. Overall, the probes 13 
show improved resistance to nucleases and proteases as well as higher specificity and affinity 14 
than DNA probes. 15 
PNA-FISH allows rapid identification of the infectious agents at both genus and species level 16 
directly from peripheral blood samples (Figure 3). Importantly, this assay provides high 17 
sensitivity and specificity with no requirement of subcultures as in conventional blood culture 18 
methods [85]. The first generation of PNA-FISH agents were used to detect and differentiate 19 
the five most common Candida species (sensitivity 97.5-98.9%, specificity 98.2-100%) in three 20 
main groups according to the wavelength of the fluorescence emission: C. albicans/C. 21 
parapsilosis (green fluorescence), C. tropicalis (yellow fluorescence) and C. glabrata/C. krusei 22 
(red fluorescence) [86]. The identification of multiple Candida species by differential 23 
fluorescence emission also provided valuable information of the resistance of the strains to 24 
antifungal treatments. Thus, whereas C. albicans and C. parapsilosis were sensitive to 25 
commonly prescribed antifungals (i.e., fluconazole, echinocandin), C. tropicalis, C. glabrata 26 
and C. krusei were more prone to become resistant to these treatments. The second 27 
generation of PNA-FISH probes significantly reduced the time needed for probe incubation 28 
(i.e., from 90 to 30 min), further shortening the time-to-result outcome. This second generation 29 
was able to distinguish the common species C. albicans (green fluorescence), C. parapsilosis 30 
(yellow fluorescence) and C. glabrata (red fluorescence) with sensitivities and specificities at 31 
around 99.7 and 98%, respectively. The high sensitivity and specificity of this PNA-FISH assay 32 
was validated in a multi-institutional study, where 244 clinical blood samples were evaluated 33 
for the selective detection of C. albicans [87]. In another study, C. albicans and C. Glabrata 34 
were identified alone or in combination with other pathogens in significantly shorter times [88].  35 
The detection of fungal pathogens by PNA-FISH typically comprises four main steps: 1) 36 
fixation of the sample to prevent loss of cell integrity, 2) hybridisation of the fluorescent probe 37 
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to the target sequence at a specific temperature (40-60ºC range), 3) washing to remove 1 
unhybridised PNA probe, and 4) detection of the probe by fluorescence microscopy. Critically, 2 
the experimental conditions during the hybridisation step (e.g., concentration, temperature, 3 
pH, salt concentration, etc.) must be optimised to ensure hybridisation and a high degree of 4 
standardisation. In an optimisation study of the 28S rRNA targeting probe (P-Ca726) for the 5 
identification of C. albicans, Kim et al. showed that the use of the denaturant formamide 6 
reduced non-specific binding and increased overall performance [89]. An important feature of 7 
PNA-FISH assays is the discrimination of C. albicans from closely related atypical species, 8 
avoiding misidentification of pathogens in blood patient samples. Oliveira and co-workers 9 
showed that C. albicans and C. dubliniensis PNA-FISH probes could be simultaneously used 10 
to identify both Candida species without cross-hybridisation [90]. Nevertheless, some cross-11 
reactivity with other non-clinically relevant Candida species has been reported in other studies 12 
(e.g., C. lambica, C. Rhodotorula mucilaginosa) [91]. The appropriate identification of Candida 13 
species is crucial to provide adequate treatment and reduce times and associated costs 14 
(Figure 3). A comparative study of PNA-FISH and routine methods in hospitalised patients 15 
with candidemia proved that the times needed to prescribe the correct therapy and the 16 
associated costs were significantly reduced after implementation of the PNA-FISH assay, with 17 
savings of over $400 per patient [92]. In another study, an evaluation of the clinical impact of 18 
a second-generation assay (i.e., PNA FISH Yeast Traffic Light assay) concluded that, after 19 
the analysis of 54 patient isolates, the implantation of the test would have led to changes in 20 
antifungal therapy in more than 29% of the cases if the results of the PNA-FISH assays had 21 
been available [93].  22 
The detection and characterisation of other fungi by PNA-FISH has also been described. 23 
Teertstra et al. reported the visualisation of Schizophyllum commune and Aspergillus niger 24 
colonies, showing the first report of PNA probes for in situ hybridisation of mRNA in 25 
filamentous fungi [94]. Subsequently, Nakada et al. reported the first localisation study of 26 
Phanerochaete chrysosporium and Postia placenta fungi in wood by FISH [95]. PNA-FISH 27 
also represents a promising strategy for the diagnosis of A. fumigatus as most current methods 28 
only allow the identification of the fungus at the genus level [96]. Finally, despite its excellent 29 
sensitivity, specificity and speed, some limitations of PNA-FISH assays must be taken into 30 
consideration: 1) assays are expensive and require experienced and well-trained individuals 31 
for correct identification of the fungi, 2) pathogen concentrations over 105 colony-forming units 32 
mL-1 are needed for adequate detection, and 3) PNA-FISH is a target-oriented assay that 33 




Figure 3. Fluorescence identification of multiple fungal species using AdvanDx PNA-2 
FISH. Multiplex fluorescence image of the five most common Candida species: C. albicans/C. 3 
parapsilosis (green fluorescence), C. tropicalis (yellow fluorescence) and C. glabrata/C. krusei 4 
(red fluorescence). Image reprinted with permission from OpGen, the manufacturer of the test. 5 
 6 
3. Alternative modalities for non-optical in vivo imaging 7 
Although the direct visualisation of cells and tissues using light has been one of the most 8 
informative approaches in diagnostic medical imaging, its limited depth of penetration (less 9 
than 1 cm) has hampered its widespread application for in vivo clinical imaging studies. This 10 
can partially overcome with the use of near-infrared dyes (i.e., emitting in the spectral range 11 
from 650 nm to 900 nm) [97, 98], which provide deeper tissue penetration and can be used 12 
for whole-body fluorescence tomography in preclinical models. 13 
Non-optical imaging modalities with limitless penetration characteristics, such as positron 14 
emission tomography (PET), magnetic resonance imaging (MRI) and computed tomography 15 
(CT), are alternative technologies with broad use in clinical imaging [99]. In the clinic, the most 16 
common reagent used for PET imaging is the 18F-labeled imaging agent [18F]-2-fluoro-2-17 
deoxy-glucose (FDG). FDG was first synthesized by Ido et al. in 1978 [100] and it is an 18 
analogue of glucose whereby the C2 hydroxyl group is replaced by the radioactive fluorine 19 
atom 18F. The accumulation of FDG reflects the metabolic requirements of cells, and as such, 20 
it has been used to detect cancer cells, which present metabolic demands that are different 21 
from most normal cells [101]. Recently FDG has been also used in PET/CT imaging for 22 
detecting and guiding management of invasive fungal infections, with improved performance 23 
14 
 
over CT alone for the localisation of infection, dissemination and response to therapy in human 1 
patients [102].  2 
The limited specificity of FDG has, however, prompted the development of reagents with 3 
higher selectivity for fungal cells in order to reduce potential off-target signals. In this context, 4 
two recent studies have demonstrated the translational potential of PET contrast agents for 5 
imaging fungi in preclinical models and in humans. Rolle et al. developed a novel probe for 6 
non-invasive detection of A. fumigatus infection in the lungs of mice using PET and MRI [103] 7 
(Figure 4). The authors generated a 64Cu-DOTA-labeled monoclonal antibody specific to A. 8 
fumigatus that allowed specific localisation of fungi in infected lungs. Notably, this new PET 9 
tracer (64Cu-DOTA-JF5) was able to distinguish fungal from bacterial lung infections and, 10 
unlike FDG, discriminated Aspergillosis from generic increases in metabolic activity 11 
associated with lung inflammation. Peptides, which are smaller constructs than antibodies, 12 
typically offer improved biodistribution for in vivo studies. This has been recently proven by 13 
Ebenhan et al. with a first in-human study of 68Ga-NOTA functionalised ubiquicidin (UBI29-41), 14 
a cationic-rich peptide with high affinity for fungal cells [104]. Initial assays assessed the 15 
performance of the tracer in vitro using different bacterial and fungal strains, followed by 16 
PET/CT-imaging biodistribution and pharmacokinetics studies on non-human primates. 17 
Finally, 68Ga-NOTA-ubiquicidin was tested in a small cohort of humans and proven as nontoxic 18 






Figure 4. A disease-specific PET-tracer for the detection of A. fumigatus lung infection. 2 
a) Sagittal maximum intensity projections of MRI and fused PET/MRI images of PBS-treated 3 
mice and S. pneumoniae-, Y. enterocolitica- and A. fumigatus-infected mice injected with 64Cu-4 
DOTA-JF5 (48 h after infection). Tracer injection demonstrates highly specific accumulation 5 
in A. fumigatus-infected lung tissue compared to bacterial-infected or sham-treated animals. 6 
b) Quantification of in vivo PET images with significantly higher uptake of 64Cu-DOTA-JF5 in 7 
the lungs of A. fumigatus-infected animals compared to the lungs of control animals. c) Ex vivo 8 
biodistribution show significantly higher uptake of 64Cu-DOTA-JF5 in the lungs of A. fumigatus-9 
infected animals compared to the lungs of control animals. Black bars, PBS-treated controls; 10 
blue bars, S. pneumoniae-infected mice; orange bars, Y. enterocolitica-infected mice; red 11 
bars, A. fumigatus-infected mice. Reproduced from reference 103. 12 
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Table 1. Summary table of peptides discussed in this article. 1 
 2 













GMA4-C GRCRGFRRRCFCTTHC 42 
GMA4-L RGFRRR 42 
BP15 KKLFKKILKVL 43,44 
VS2 KWFWKFWK 45 
VS3 KWFWKFWKFVK 45 
PAF26 RKKWFW 50-52 
Peptide 8 c[RKKW(BODIPY)FWG] 74 
Histatin-5 DSHAKRHHGYKRKFHEKHHSHRGY 50-52 
UBI29-41 TGRAKRRMQYNRR 104 
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 53-56 
CATH-2 RFGRFLRKIRRFRPKVTITIQGSARF 53-56 






The high sensitivity, multiplexing capabilities and low cost of fluorescence-based analytical 2 
techniques have favoured the emergence of optical imaging as a complementary tool to well-3 
established clinical imaging modalities, such as MRI, PET and CT. A key aspect in the 4 
application of optical imaging involves the preparation of highly specific molecular probes for 5 
direct visualisation of fungal pathogens under live-cell conditions. To this end, fluorescent 6 
peptides have emerged as powerful scaffolds for both mechanism-oriented biological studies 7 
as well as clinical use. Peptide-based probes are highly versatile and amenable to 8 
combinatorial chemistry, offering the possibility to incorporate variable fluorescent labels at 9 
will to suit different applications. Peptides also exhibit low immunogenicity and generally good 10 
biocompatibility with cells and tissues, being ideal for non-invasive mechanistic cell-based 11 
assays as well as in vivo imaging studies. With our improved understanding of protein-protein 12 
interactions, peptide chemists will be able to design novel peptide probes as enhanced 13 
diagnostic tools and therapeutics for direct patient benefit. 14 
 15 
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